Printer Friendly

Breakthrough for hepatitis vaccine.

Cuba has developed the first monoclonal antibody from transgenic plants--dubbed a "plantibody"--used in making a human vaccine, reports AFP (June 26, 2006):

The antibody, CB-Hep.1, is from an "ancestor" of the tobacco plant. It replaces an antibody obtained from mice in Cuba's manufacturing of the hepatitis B vaccine, researchers said, Carlos Borroto, deputy director at Cuba's Biotechnology and Genetic Engineering Center (CIGB) here, said the plantibody won approval from Cuba's medication quality control agency. CB-Hep.1 is the first plantibody authorized anywhere in the world for manufacturing a vaccine. It is just the second approved for human use, after one approved in the US for treating tooth decay;

The plantibody won approval on April 11 and is being used in manufacturing the vaccine. Borroto said "145 million doses have been exploited and not a single problem in their use has been reported." Cuba, he added, has several plantibody projects, including one to be used as a cancer treatment, from the same plant, noting that "a number of major international companies are looking for a partnership with us."
COPYRIGHT 2006 Caribbean Update, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:development of hepatitis B vaccine
Publication:Caribbean Update
Article Type:Brief article
Geographic Code:1USA
Date:Aug 1, 2006
Words:179
Previous Article:Senior party leader jailed.
Next Article:Backdoor route to U.S.
Topics:


Related Articles
Oral vaccine sought for hepatitis B.
Granted partial immunity from hepatitis?
Hepatitis falls to vaccine, malaria doesn't.
Preventing the spread of hepatitis B: correctional facilities offer opportunity to vaccinate at-risk juveniles and adults.
Shots in the dark: who should decide which vaccinations children receive?
Dynavax and Triangle conduct successful hepatitis B vaccine study.
Epimmune obtains patent for hepatitis B vaccines.
Hepatitis B in women: domestically and internationally.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters